🕷️ Crawler Inspector

URL Lookup

Direct Parameter Lookup

Raw Queries and Responses

1. Shard Calculation

Query:

Response:

Calculated Shard: 170 (from laksa038)

2. Crawled Status Check

Query:

curl -X POST \
  'http://laksa170.int.ahrefs:8124/' \
  -H 'Content-Type: text/plain' \
  -H 'X-ClickHouse-Database: crawler3' \
  -H 'Authorization: Basic YXBpOg==' \
  -d 'SELECT getAhrefsURLFromUnparsed(src_unparsed) AS found_url, ifNull(toUnixTimestamp(download_stamp), 0) AS crawl_time, ifNull(toUnixTimestamp(props_url_first_seen), 0) AS first_indexed_time, download_http_code AS http_code, src_unparsed AS src_unparsed, src_root_hash AS src_root_hash, history_drop_reason AS history_drop_reason, meta_title AS meta_title, meta_descriptions AS meta_descriptions, attrs_boilerpipe_text AS attrs_boilerpipe_text, attrs_markdown AS attrs_markdown, attrs_readable_markdown AS attrs_readable_markdown, meta_canonical AS meta_canonical FROM crawler3.page_info_local FINAL PREWHERE (src_root_hash, src_unparsed) IN ((getAhrefsRootHashFromUnparsed(getAhrefsUnparsedNoserviceFromURL(\'https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments\')), getAhrefsUnparsedNoserviceFromURL(\'https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments\'))) FORMAT JSONEachRow'

Response:

{"found_url":"https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments","crawl_time":1776487399,"first_indexed_time":1678534998,"http_code":200,"src_unparsed":"org,uclahealth!www,\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments s443","src_root_hash":"15898094397791395770","history_drop_reason":null,"meta_title":"COVID-19 Outpatient Treatments | UCLA Health","meta_descriptions":["UCLA Health offers the latest treatments for the coronavirus. Read more about our COVID-19 outpatient treatments including antiviral pills, Remdesivir & more."],"attrs_boilerpipe_text":"Coronavirus Outpatient Treatments\nThere are several therapies meant to prevent COVID-19 patients with high-risk medical conditions from becoming hospitalized, as follows:\nPaxlovid:\n Paxlovid is a FDA-approved oral treatment for mild-to-moderate COVID-19. Patients with COVID-19 who have had symptoms for 5 days or fewer and are at high-risk for disease progression should consider Paxlovid under a doctor's supervision. A close evaluation of drug interactions should be reviewed prior to taking Paxlovid.\nRemdesivir:\nIf we cannot offer\nPaxlovid\ndue to potential drug interactions\n, a process is in place to offer high-risk patients who meet the below criteria a three-day course of remdesivir via IV through our outpatient treatment program.\nThree days of IV remdesivir has been shown to reduce the risk of hospitalization by 87% and is similar in efficacy to Paxlovid.\nWhile\nPaxlovid \nis easier to administer, \nthe National Institutes of Health (NIH) lists three days of remdesivir as an\noption\nLink is external, Link opens in new window\nfor patients at risk of COVID-19 disease progression. \nMonoclonal antibody therapies:\n As of Nov. 21, 2022, UCLA Health no longer uses bebtelovimab to treat COVID-19, as\n the currently circulating strains of the omicron variant are resistant to this monoclonal antibody therapy.\nMolnupiravir: \nHigh-risk patients with COVID-19 who are ineligible for Paxlovid and don't meet the high-risk criteria for remdesivir may be given an anti-viral pill called molnupiravir (Lagevrio) to prevent hospitalization.\nWatch video: outpatient COVID-19 therapies\nCost information for COVID outpatient treatments:\nCOVID-19 medications are currently being provided to patients at no cost\n. While we are billing insurers for the administration of remdesivir, there should be no cost share for patients.\nWant more information?\nPlease reach out to your primary care physician if you have questions about outpatient COVID-19 therapies. Please see the\nCOVID-19 vaccine info hub\nfor information about the available vaccines.\nHigh-risk criteria for remdesivir:\nPatients with the following high-risk conditions who are otherwise ineligible for Paxlovid due to drug interactions or a creatine clearance of <30 may be eligible to receive remdesivir through our outpatient treatment program.\nPatients who are within one year of receiving B-cell depleting therapies (e.g., rituximab, ocrelizumab, ofatumumab, alemtuzumab)\nPatients receiving Bruton tyrosine kinase inhibitors (e.g. ibrutinib, acalabrutinib, zanubrutinib)\nChimeric antigen receptor T cell recipients (CAR-T)\nPost-hematopoietic cell transplant recipients who have chronic graft versus host disease or who are taking immunosuppressive medications for another indication\nPatients with hematologic malignancies who are on active chemotherapy\nAny solid organ transplant recipient\nPatients with severe combined immunodeficiencies\nPatients with untreated HIV who have a CD4 T lymphocyte cell count <200 cells\/mm3\nPatients in active cancer treatment for non-hematologic malignancies (e.g. myelosuppressive chemotherapy)\nPost-hematopoietic cell transplant recipients who received treatment within two years without GVHD \/ not taking immunosuppressive medications for another indication\nPatients actively being treated with high-dose corticosteroids of more than 20 mg daily for at least two weeks, or actively taking other drugs (within one month) that may suppress their immune response\nPatients with pulmonary arterial hypertension on phosphodiesterase inhibitors and on chronic oxygen\nPatients who are unvaccinated who have traditional high-risk co-morbid conditions such as obesity or heart, kidney or lung disease\nMonoclonal antibody therapy for pre-exposure prophylaxis\nAs of Nov. 21, 2022, UCLA Health will no longer accept new referrals for AstraZeneca's Evusheld (tixagevimab\/cilgavimab), the FDA authorized monoclonal antibody for pre-exposure prevention of COVID-19, as the currently circulating omicron subvariants are resistant to this therapy. \nPlease contact your primary care physician if you have any questions.","attrs_markdown":"[Skip to main content](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#main-content)\n\nExplore links (header)\n\nExplore UCLA Health\n\n- [UCLA Health Home](https:\/\/www.uclahealth.org\/)\n- [About Us](https:\/\/www.uclahealth.org\/discover\/about)\n- [Cancer Center](https:\/\/www.uclahealth.org\/cancer)\n- [Hospitals & Clinics](https:\/\/www.uclahealth.org\/locations)\n- [School of Medicine](https:\/\/medschool.ucla.edu\/)\n- [Academic Departments](https:\/\/www.uclahealth.org\/departments)\n- [News & Insights](https:\/\/www.uclahealth.org\/news)\n- [Community & Equity](https:\/\/www.uclahealth.org\/community-equity)\n\n[Refer a Patient](https:\/\/www.uclahealth.org\/discover\/healthcare-professionals)\n\nUniversal links (header)\n\n[myUCLAhealth](https:\/\/www.uclahealth.org\/myuclahealth\/nojs \"myUCLAhealth Login.\")\n\n[Contact Us](https:\/\/www.uclahealth.org\/contact-us)\n\nTranslate\n\n- [English](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [العربية](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [中文](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [Italiano](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [日本語](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [한국어](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [فارسی](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [Русский](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [Español](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [Tiếng Việt](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n\nTranslate\n\n- [English](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [العربية](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [中文](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [Italiano](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [日本語](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [한국어](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [فارسی](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [Русский](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [Español](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n- [Tiếng Việt](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments#nolink)\n\n[![UCLA Health](https:\/\/www.uclahealth.org\/themes\/custom\/uclahealth\/dist\/images\/ucla-health-logo.svg)](https:\/\/www.uclahealth.org\/)\n\nPrimary navigation\n\n[Find Care](https:\/\/www.uclahealth.org\/find-care\/appointments)\n\n\\>\n\n- [Find a Doctor](https:\/\/www.uclahealth.org\/providers)\n- [Find a Location](https:\/\/www.uclahealth.org\/locations)\n- [Virtual Care](https:\/\/www.uclahealth.org\/find-care\/appointments\/virtual-care)\n- [Make an Appointment](https:\/\/www.uclahealth.org\/find-care\/appointments)\n- [Second Opinion Consults](https:\/\/www.uclahealth.org\/find-care\/appointments\/second-opinion-consults)\n- [Medical Services](https:\/\/www.uclahealth.org\/medical-services)\n- [Cancer Medical Services](https:\/\/www.uclahealth.org\/cancer\/cancer-services)\n- [Clinical Trials](https:\/\/www.uclahealth.org\/clinical-trials)\n- [Wellness & Routine Care](https:\/\/www.uclahealth.org\/patient-resources\/support-information\/patient-education\/annual-health-wellness-screenings)\n\n[Patient Resources](https:\/\/www.uclahealth.org\/patient-resources)\n\n\\>\n\n- [Prepare for Your Visit](https:\/\/www.uclahealth.org\/patient-resources\/prepare-your-visit)\n- [Billing & Insurance](https:\/\/www.uclahealth.org\/patient-resources\/billing-insurance)\n- [Support & Information](https:\/\/www.uclahealth.org\/patient-resources\/support-information)\n- [Patient Portal (myUCLAhealth) & Medical Records](https:\/\/www.uclahealth.org\/patient-resources\/medical-records)\n- [Help Paying Your Bill](https:\/\/www.uclahealth.org\/patient-resources\/billing-insurance\/financial-assistance-program\/hospital-services-help-paying-your-bill)\n- [International Services](https:\/\/www.uclahealth.org\/international-services)\n- [Patient Scam Alert](https:\/\/www.uclahealth.org\/patient-resources\/patient-scam-alert)\n\n[Locations](https:\/\/www.uclahealth.org\/locations\/search)\n\n\\>\n\n- [Immediate Care](https:\/\/www.uclahealth.org\/locations\/immediate-care)\n- [Primary Care](https:\/\/www.uclahealth.org\/locations\/search?s=&f%5B0%5D=type%3A741)\n- [Pediatric Care](https:\/\/www.uclahealth.org\/locations\/search?s=&f%5B0%5D=type%3A781)\n- [Cancer Care](https:\/\/www.uclahealth.org\/cancer\/locations)\n- [Surgical Centers](https:\/\/www.uclahealth.org\/locations\/search?s=&f%5B0%5D=type%3A761 \"See a list of outpatient surgical centers at UCLA Health\")\n- [Imaging\/Radiology](https:\/\/www.uclahealth.org\/locations\/search?s=&f%5B0%5D=type%3A786)\n- [Hospitals](https:\/\/www.uclahealth.org\/locations\/search?f%5B0%5D=type%3A751)\n- [All Locations](https:\/\/www.uclahealth.org\/locations)\n\n[Discover](https:\/\/www.uclahealth.org\/discover\/about)\n\n\\>\n\n- [About UCLA Health](https:\/\/www.uclahealth.org\/discover\/about)\n- [News & Insights](https:\/\/www.uclahealth.org\/news)\n- [Patient Stories](https:\/\/www.uclahealth.org\/news\/search?f%5B0%5D=type%3A80636)\n- [Events Calendar](https:\/\/www.uclahealth.org\/events)\n- [Donate to UCLA Health](https:\/\/www.uclahealth.org\/giving)\n- [Work at UCLA Health](https:\/\/www.uclahealth.org\/human-resources)\n- [For Health Care Professionals](https:\/\/www.uclahealth.org\/discover\/healthcare-professionals)\n- [Connect with UCLA Health](https:\/\/www.uclahealth.org\/discover-ucla-health\/connect)\n\n[Find a Doctor](https:\/\/www.uclahealth.org\/providers)\n\nPrimary navigation (mobile)\n\n[Find a Doctor](https:\/\/www.uclahealth.org\/providers)\n\n[Find Care](https:\/\/www.uclahealth.org\/find-care\/appointments)\n\n- [Find a Doctor](https:\/\/www.uclahealth.org\/providers)\n- [Find a Location](https:\/\/www.uclahealth.org\/locations)\n- [Virtual Care](https:\/\/www.uclahealth.org\/find-care\/appointments\/virtual-care)\n- [Make an Appointment](https:\/\/www.uclahealth.org\/find-care\/appointments)\n- [Second Opinion Consults](https:\/\/www.uclahealth.org\/find-care\/appointments\/second-opinion-consults)\n- [Medical Services](https:\/\/www.uclahealth.org\/medical-services)\n- [Cancer Medical Services](https:\/\/www.uclahealth.org\/cancer\/cancer-services)\n- [Clinical Trials](https:\/\/www.uclahealth.org\/clinical-trials)\n- [Wellness & Routine Care](https:\/\/www.uclahealth.org\/patient-resources\/support-information\/patient-education\/annual-health-wellness-screenings)\n\n[Patient Resources](https:\/\/www.uclahealth.org\/patient-resources)\n\n- [Prepare for Your Visit](https:\/\/www.uclahealth.org\/patient-resources\/prepare-your-visit)\n- [Billing & Insurance](https:\/\/www.uclahealth.org\/patient-resources\/billing-insurance)\n- [Support & Information](https:\/\/www.uclahealth.org\/patient-resources\/support-information)\n- [Patient Portal (myUCLAhealth) & Medical Records](https:\/\/www.uclahealth.org\/patient-resources\/medical-records)\n- [Help Paying Your Bill](https:\/\/www.uclahealth.org\/patient-resources\/billing-insurance\/financial-assistance-program\/hospital-services-help-paying-your-bill)\n- [International Services](https:\/\/www.uclahealth.org\/international-services)\n- [Patient Scam Alert](https:\/\/www.uclahealth.org\/patient-resources\/patient-scam-alert)\n\n[Locations](https:\/\/www.uclahealth.org\/locations\/search)\n\n- [Immediate Care](https:\/\/www.uclahealth.org\/locations\/immediate-care)\n- [Primary Care](https:\/\/www.uclahealth.org\/locations\/search?s=&f%5B0%5D=type%3A741)\n- [Pediatric Care](https:\/\/www.uclahealth.org\/locations\/search?s=&f%5B0%5D=type%3A781)\n- [Cancer Care](https:\/\/www.uclahealth.org\/cancer\/locations)\n- [Surgical Centers](https:\/\/www.uclahealth.org\/locations\/search?s=&f%5B0%5D=type%3A761 \"See a list of outpatient surgical centers at UCLA Health\")\n- [Imaging\/Radiology](https:\/\/www.uclahealth.org\/locations\/search?s=&f%5B0%5D=type%3A786)\n- [Hospitals](https:\/\/www.uclahealth.org\/locations\/search?f%5B0%5D=type%3A751)\n- [All Locations](https:\/\/www.uclahealth.org\/locations)\n\n[Discover](https:\/\/www.uclahealth.org\/discover\/about)\n\n- [About UCLA Health](https:\/\/www.uclahealth.org\/discover\/about)\n- [News & Insights](https:\/\/www.uclahealth.org\/news)\n- [Patient Stories](https:\/\/www.uclahealth.org\/news\/search?f%5B0%5D=type%3A80636)\n- [Events Calendar](https:\/\/www.uclahealth.org\/events)\n- [Donate to UCLA Health](https:\/\/www.uclahealth.org\/giving)\n- [Work at UCLA Health](https:\/\/www.uclahealth.org\/human-resources)\n- [For Health Care Professionals](https:\/\/www.uclahealth.org\/discover\/healthcare-professionals)\n- [Connect with UCLA Health](https:\/\/www.uclahealth.org\/discover-ucla-health\/connect)\n\nExplore links (mobile)\n\nExplore UCLA Health\n\n- [UCLA Health Home](https:\/\/www.uclahealth.org\/)\n- [About Us](https:\/\/www.uclahealth.org\/discover\/about)\n- [Cancer Center](https:\/\/www.uclahealth.org\/cancer)\n- [Hospitals & Clinics](https:\/\/www.uclahealth.org\/locations)\n- [School of Medicine](https:\/\/medschool.ucla.edu\/)\n- [Academic Departments](https:\/\/www.uclahealth.org\/departments)\n- [News & Insights](https:\/\/www.uclahealth.org\/news)\n- [Community & Equity](https:\/\/www.uclahealth.org\/community-equity)\n\n[Refer a Patient](https:\/\/www.uclahealth.org\/discover\/healthcare-professionals)\n\nUniversal links (mobile)\n\n[myUCLAhealth](https:\/\/www.uclahealth.org\/myuclahealth\/nojs \"myUCLAhealth Login.\")\n\n[Contact Us](https:\/\/www.uclahealth.org\/contact-us)\n\nBreadcrumb\n\n1. [Home](https:\/\/www.uclahealth.org\/)\n# COVID-19 Outpatient Treatments\n\n## Sub-navigation\n## [COVID-19 Info](https:\/\/www.uclahealth.org\/treatment-options\/coronavirus)\n- [Vaccine Info Hub](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-vaccine-info-hub)\n- [COVID-19 Positive](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-positive)\n- [COVID-19 Outpatient Treatments](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments)\n- [FAQ](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq)\n  \n  - [Symptoms](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq\/symptoms)\n  - [Testing](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq\/testing)\n  - [COVID-19 Positive](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq\/covid-19-positive)\n  - [Treatment](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq\/treatment)\n  - [Vaccine](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq\/vaccine)\n  - [Immunity](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq\/immunity)\n  - [Appointments & Visitor Guidelines](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq\/appointments-visitor-guidelines)\n  - [Pregnancy & COVID-19](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq\/pregnancy-covid-19)\n- [Addressing Concerns](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-vaccine-addressing-concerns)\n\n[COVID-19 Info](https:\/\/www.uclahealth.org\/treatment-options\/coronavirus)\n\n- [Vaccine Info Hub](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-vaccine-info-hub)\n- [COVID-19 Positive](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-positive)\n- [COVID-19 Outpatient Treatments](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-outpatient-treatments)\n- [FAQ](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq)\n  - [Symptoms](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq\/symptoms)\n  - [Testing](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq\/testing)\n  - [COVID-19 Positive](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq\/covid-19-positive)\n  - [Treatment](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq\/treatment)\n  - [Vaccine](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq\/vaccine)\n  - [Immunity](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq\/immunity)\n  - [Appointments & Visitor Guidelines](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq\/appointments-visitor-guidelines)\n  - [Pregnancy & COVID-19](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/faq\/pregnancy-covid-19)\n- [Addressing Concerns](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-vaccine-addressing-concerns)\n\n## Coronavirus Outpatient Treatments\nThere are several therapies meant to prevent COVID-19 patients with high-risk medical conditions from becoming hospitalized, as follows:\n\n**Paxlovid:** Paxlovid is a FDA-approved oral treatment for mild-to-moderate COVID-19. Patients with COVID-19 who have had symptoms for 5 days or fewer and are at high-risk for disease progression should consider Paxlovid under a doctor's supervision. A close evaluation of drug interactions should be reviewed prior to taking Paxlovid.\n\n**Remdesivir:** If we cannot offer Paxlovid due to potential drug interactions, a process is in place to offer high-risk patients who meet the below criteria a three-day course of remdesivir via IV through our outpatient treatment program. Three days of IV remdesivir has been shown to reduce the risk of hospitalization by 87% and is similar in efficacy to Paxlovid. While Paxlovid is easier to administer, [the National Institutes of Health (NIH) lists three days of remdesivir as an option Link is external, Link opens in new window](https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/statement-on-therapies-for-high-risk-nonhospitalized-patients\/) for patients at risk of COVID-19 disease progression.\n\n**Monoclonal antibody therapies:** As of Nov. 21, 2022, UCLA Health no longer uses bebtelovimab to treat COVID-19, as the currently circulating strains of the omicron variant are resistant to this monoclonal antibody therapy.\n\n**Molnupiravir:** High-risk patients with COVID-19 who are ineligible for Paxlovid and don't meet the high-risk criteria for remdesivir may be given an anti-viral pill called molnupiravir (Lagevrio) to prevent hospitalization.\n\nWatch video: outpatient COVID-19 therapies\n\n**Cost information for COVID outpatient treatments:** COVID-19 medications are currently being provided to patients at no cost[. While we are billing insurers for the administration of remdesivir, there should be no cost share for patients.]()\n\n**Want more information?** Please reach out to your primary care physician if you have questions about outpatient COVID-19 therapies. Please see the [COVID-19 vaccine info hub](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-vaccine-info-hub) for information about the available vaccines.\n\n### High-risk criteria for remdesivir:\nPatients with the following high-risk conditions who are otherwise ineligible for Paxlovid due to drug interactions or a creatine clearance of \\<30 may be eligible to receive remdesivir through our outpatient treatment program.\n\n- Patients who are within one year of receiving B-cell depleting therapies (e.g., rituximab, ocrelizumab, ofatumumab, alemtuzumab)\n- Patients receiving Bruton tyrosine kinase inhibitors (e.g. ibrutinib, acalabrutinib, zanubrutinib)\n- Chimeric antigen receptor T cell recipients (CAR-T)\n- Post-hematopoietic cell transplant recipients who have chronic graft versus host disease or who are taking immunosuppressive medications for another indication\n- Patients with hematologic malignancies who are on active chemotherapy\n- Any solid organ transplant recipient\n- Patients with severe combined immunodeficiencies\n- Patients with untreated HIV who have a CD4 T lymphocyte cell count \\<200 cells\/mm3\n- Patients in active cancer treatment for non-hematologic malignancies (e.g. myelosuppressive chemotherapy)\n- Post-hematopoietic cell transplant recipients who received treatment within two years without GVHD \/ not taking immunosuppressive medications for another indication\n- Patients actively being treated with high-dose corticosteroids of more than 20 mg daily for at least two weeks, or actively taking other drugs (within one month) that may suppress their immune response\n- Patients with pulmonary arterial hypertension on phosphodiesterase inhibitors and on chronic oxygen\n- Patients who are unvaccinated who have traditional high-risk co-morbid conditions such as obesity or heart, kidney or lung disease\n### Monoclonal antibody therapy for pre-exposure prophylaxis\nAs of Nov. 21, 2022, UCLA Health will no longer accept new referrals for AstraZeneca's Evusheld (tixagevimab\/cilgavimab), the FDA authorized monoclonal antibody for pre-exposure prevention of COVID-19, as the currently circulating omicron subvariants are resistant to this therapy.\n\nPlease contact your primary care physician if you have any questions.\n\n[![UCLA Health](https:\/\/www.uclahealth.org\/themes\/custom\/uclahealth\/dist\/images\/ucla-health-logo-footer.svg)](https:\/\/www.uclahealth.org\/)\n\n- ### CONNECT WITH US\n  - [Contact Us](https:\/\/www.uclahealth.org\/contact-us)\n  - [Share Your Feedback](https:\/\/connect.uclahealth.org\/send-a-care-compliment\/)\n  - [International Services](https:\/\/www.uclahealth.org\/international-services)\n  - [中文](https:\/\/cn.uclahealth.org\/)\n  - [العربية](https:\/\/mena.uclahealth.org\/)\n  - [myUCLAhealth](https:\/\/www.uclahealth.org\/myuclahealth\/nojs)\n  - [Get the UCLA Health Apps](https:\/\/www.uclahealth.org\/patient-resources\/support-information\/apps)\n- ### FIND CARE\n  - [Find a Doctor](https:\/\/www.uclahealth.org\/providers)\n  - [Find a Location](https:\/\/www.uclahealth.org\/locations \"\/patients-families\/find-a-location\")\n  - [Immediate Care](https:\/\/www.uclahealth.org\/locations\/immediate-care)\n  - [Emergency Care](https:\/\/www.uclahealth.org\/emergency)\n  - [Make an Appointment](https:\/\/www.uclahealth.org\/find-care\/appointments)\n  - [Medical Services](https:\/\/www.uclahealth.org\/medical-services)\n  - [Clinical Trials](https:\/\/www.uclahealth.org\/clinical-trials)\n- ### PATIENT RESOURCES\n  - [Prepare for Your Visit](https:\/\/www.uclahealth.org\/patient-resources\/prepare-your-visit)\n  - [Visitor Guidelines](https:\/\/www.uclahealth.org\/patient-resources\/visitor-guidelines)\n  - [Patient Education](https:\/\/www.uclahealth.org\/patient-resources\/support-information\/patient-education)\n  - [Billing & Insurance](https:\/\/www.uclahealth.org\/patient-resources\/billing-insurance)\n  - [Help Paying Your Bill](https:\/\/www.uclahealth.org\/patient-resources\/billing-insurance\/financial-assistance-program\/hospital-services-help-paying-your-bill)\n  - [Price Transparency](https:\/\/www.uclahealth.org\/patient-resources\/billing-insurance\/price-transparency\/machine-readable-files)\n  - [Support & Information](https:\/\/www.uclahealth.org\/patient-resources\/support-information)\n  - [COVID-19 Info](https:\/\/www.uclahealth.org\/treatment-options\/coronavirus)\n  - [Wellness & Routine Care](https:\/\/www.uclahealth.org\/patient-resources\/support-information\/patient-education\/annual-health-wellness-screenings)\n- ### DISCOVER UCLA HEALTH\n  - [About UCLA Health](https:\/\/www.uclahealth.org\/discover\/about)\n  - [Departments](https:\/\/www.uclahealth.org\/departments)\n  - [News, Insights and Patient Stories](https:\/\/www.uclahealth.org\/news)\n  - [For Health Care Professionals](https:\/\/www.uclahealth.org\/discover\/healthcare-professionals)\n  - [Community, Equity and Inclusive Excellence](https:\/\/www.uclahealth.org\/discover\/about\/hedi)\n  - [Contact Media Team](https:\/\/www.uclahealth.org\/news\/journalist-resources)\n  - [Donate to UCLA Health](https:\/\/www.uclahealth.org\/giving)\n  - [Work at UCLA Health](https:\/\/www.uclahealthcareers.org\/)\n  - [Volunteer for UCLA Health](https:\/\/www.uclahealth.org\/volunteer)\n\n- [Facebook](https:\/\/www.facebook.com\/uclahealth)\n- [X-Twitter](https:\/\/x.com\/uclahealth)\n- [Instagram](https:\/\/instagram.com\/uclahealth)\n- [YouTube](https:\/\/youtube.com\/ucla-health)\n- [LinkedIn](https:\/\/linkedin.com\/company\/ucla-health)\n- [Weibo](https:\/\/weibo.com\/UCLAHealth)\n\n## Policy links (footer)\n- [HIPAA Notice](https:\/\/www.uclahealth.org\/privacy-practices)\n- [Privacy Notice](https:\/\/www.uclahealth.org\/privacy-notice)\n- [Nondiscrimination](https:\/\/www.uclahealth.org\/nondiscrimination)\n- [Report Misconduct](https:\/\/www.uclahealth.org\/reporting-misconduct)\n- [We listen. We care.](https:\/\/www.uclahealth.org\/patient-resources\/support-information\/patient-experience\/we-listen-we-care)\n\n© 2026 UCLA Health","attrs_readable_markdown":"## Coronavirus Outpatient Treatments\nThere are several therapies meant to prevent COVID-19 patients with high-risk medical conditions from becoming hospitalized, as follows:\n\n**Paxlovid:** Paxlovid is a FDA-approved oral treatment for mild-to-moderate COVID-19. Patients with COVID-19 who have had symptoms for 5 days or fewer and are at high-risk for disease progression should consider Paxlovid under a doctor's supervision. A close evaluation of drug interactions should be reviewed prior to taking Paxlovid.\n\n**Remdesivir:** If we cannot offer Paxlovid due to potential drug interactions, a process is in place to offer high-risk patients who meet the below criteria a three-day course of remdesivir via IV through our outpatient treatment program. Three days of IV remdesivir has been shown to reduce the risk of hospitalization by 87% and is similar in efficacy to Paxlovid. While Paxlovid is easier to administer, [the National Institutes of Health (NIH) lists three days of remdesivir as an option Link is external, Link opens in new window](https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/statement-on-therapies-for-high-risk-nonhospitalized-patients\/) for patients at risk of COVID-19 disease progression.\n\n**Monoclonal antibody therapies:** As of Nov. 21, 2022, UCLA Health no longer uses bebtelovimab to treat COVID-19, as the currently circulating strains of the omicron variant are resistant to this monoclonal antibody therapy.\n\n**Molnupiravir:** High-risk patients with COVID-19 who are ineligible for Paxlovid and don't meet the high-risk criteria for remdesivir may be given an anti-viral pill called molnupiravir (Lagevrio) to prevent hospitalization.\n\nWatch video: outpatient COVID-19 therapies\n\n**Cost information for COVID outpatient treatments:** COVID-19 medications are currently being provided to patients at no cost[. While we are billing insurers for the administration of remdesivir, there should be no cost share for patients.]()\n\n**Want more information?** Please reach out to your primary care physician if you have questions about outpatient COVID-19 therapies. Please see the [COVID-19 vaccine info hub](https:\/\/www.uclahealth.org\/treatment-options\/covid-19-info\/covid-19-vaccine-info-hub) for information about the available vaccines.\n\n### High-risk criteria for remdesivir:\nPatients with the following high-risk conditions who are otherwise ineligible for Paxlovid due to drug interactions or a creatine clearance of \\<30 may be eligible to receive remdesivir through our outpatient treatment program.\n\n- Patients who are within one year of receiving B-cell depleting therapies (e.g., rituximab, ocrelizumab, ofatumumab, alemtuzumab)\n- Patients receiving Bruton tyrosine kinase inhibitors (e.g. ibrutinib, acalabrutinib, zanubrutinib)\n- Chimeric antigen receptor T cell recipients (CAR-T)\n- Post-hematopoietic cell transplant recipients who have chronic graft versus host disease or who are taking immunosuppressive medications for another indication\n- Patients with hematologic malignancies who are on active chemotherapy\n- Any solid organ transplant recipient\n- Patients with severe combined immunodeficiencies\n- Patients with untreated HIV who have a CD4 T lymphocyte cell count \\<200 cells\/mm3\n- Patients in active cancer treatment for non-hematologic malignancies (e.g. myelosuppressive chemotherapy)\n- Post-hematopoietic cell transplant recipients who received treatment within two years without GVHD \/ not taking immunosuppressive medications for another indication\n- Patients actively being treated with high-dose corticosteroids of more than 20 mg daily for at least two weeks, or actively taking other drugs (within one month) that may suppress their immune response\n- Patients with pulmonary arterial hypertension on phosphodiesterase inhibitors and on chronic oxygen\n- Patients who are unvaccinated who have traditional high-risk co-morbid conditions such as obesity or heart, kidney or lung disease\n### Monoclonal antibody therapy for pre-exposure prophylaxis\nAs of Nov. 21, 2022, UCLA Health will no longer accept new referrals for AstraZeneca's Evusheld (tixagevimab\/cilgavimab), the FDA authorized monoclonal antibody for pre-exposure prevention of COVID-19, as the currently circulating omicron subvariants are resistant to this therapy.\n\nPlease contact your primary care physician if you have any questions.","meta_canonical":null}

3. Robots.txt Check

Query:

Response:

4. Spam/Ban Check

Query:

Response:

5. Seen Status Check

ℹ️ Skipped - page is already crawled

📄

INDEXABLE

✅

CRAWLED

1 day ago

🤖

ROBOTS ALLOWED

Page Info Filters

Filter	Status	Condition	Details
HTTP status	PASS	`download_http_code = 200`	HTTP 200
Age cutoff	PASS	`download_stamp > now() - 6 MONTH`	0 months ago
History drop	PASS	`isNull(history_drop_reason)`	No drop reason
Spam/ban	PASS	`fh_dont_index != 1 AND ml_spam_score = 0`	ml_spam_score=0
Canonical	PASS	`meta_canonical IS NULL OR = '' OR = src_unparsed`	Not set

Page Details

Property	Value
URL	https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments
Last Crawled	2026-04-18 04:43:19 (1 day ago)
First Indexed	2023-03-11 11:43:18 (3 years ago)
HTTP Status Code	200
Meta Title	COVID-19 Outpatient Treatments \| UCLA Health
Meta Description	UCLA Health offers the latest treatments for the coronavirus. Read more about our COVID-19 outpatient treatments including antiviral pills, Remdesivir & more.
Meta Canonical	null
Boilerpipe Text	Coronavirus Outpatient Treatments There are several therapies meant to prevent COVID-19 patients with high-risk medical conditions from becoming hospitalized, as follows: Paxlovid: Paxlovid is a FDA-approved oral treatment for mild-to-moderate COVID-19. Patients with COVID-19 who have had symptoms for 5 days or fewer and are at high-risk for disease progression should consider Paxlovid under a doctor's supervision. A close evaluation of drug interactions should be reviewed prior to taking Paxlovid. Remdesivir: If we cannot offer Paxlovid due to potential drug interactions , a process is in place to offer high-risk patients who meet the below criteria a three-day course of remdesivir via IV through our outpatient treatment program. Three days of IV remdesivir has been shown to reduce the risk of hospitalization by 87% and is similar in efficacy to Paxlovid. While Paxlovid is easier to administer, the National Institutes of Health (NIH) lists three days of remdesivir as an option Link is external, Link opens in new window for patients at risk of COVID-19 disease progression. Monoclonal antibody therapies: As of Nov. 21, 2022, UCLA Health no longer uses bebtelovimab to treat COVID-19, as the currently circulating strains of the omicron variant are resistant to this monoclonal antibody therapy. Molnupiravir: High-risk patients with COVID-19 who are ineligible for Paxlovid and don't meet the high-risk criteria for remdesivir may be given an anti-viral pill called molnupiravir (Lagevrio) to prevent hospitalization. Watch video: outpatient COVID-19 therapies Cost information for COVID outpatient treatments: COVID-19 medications are currently being provided to patients at no cost . While we are billing insurers for the administration of remdesivir, there should be no cost share for patients. Want more information? Please reach out to your primary care physician if you have questions about outpatient COVID-19 therapies. Please see the COVID-19 vaccine info hub for information about the available vaccines. High-risk criteria for remdesivir: Patients with the following high-risk conditions who are otherwise ineligible for Paxlovid due to drug interactions or a creatine clearance of <30 may be eligible to receive remdesivir through our outpatient treatment program. Patients who are within one year of receiving B-cell depleting therapies (e.g., rituximab, ocrelizumab, ofatumumab, alemtuzumab) Patients receiving Bruton tyrosine kinase inhibitors (e.g. ibrutinib, acalabrutinib, zanubrutinib) Chimeric antigen receptor T cell recipients (CAR-T) Post-hematopoietic cell transplant recipients who have chronic graft versus host disease or who are taking immunosuppressive medications for another indication Patients with hematologic malignancies who are on active chemotherapy Any solid organ transplant recipient Patients with severe combined immunodeficiencies Patients with untreated HIV who have a CD4 T lymphocyte cell count <200 cells/mm3 Patients in active cancer treatment for non-hematologic malignancies (e.g. myelosuppressive chemotherapy) Post-hematopoietic cell transplant recipients who received treatment within two years without GVHD / not taking immunosuppressive medications for another indication Patients actively being treated with high-dose corticosteroids of more than 20 mg daily for at least two weeks, or actively taking other drugs (within one month) that may suppress their immune response Patients with pulmonary arterial hypertension on phosphodiesterase inhibitors and on chronic oxygen Patients who are unvaccinated who have traditional high-risk co-morbid conditions such as obesity or heart, kidney or lung disease Monoclonal antibody therapy for pre-exposure prophylaxis As of Nov. 21, 2022, UCLA Health will no longer accept new referrals for AstraZeneca's Evusheld (tixagevimab/cilgavimab), the FDA authorized monoclonal antibody for pre-exposure prevention of COVID-19, as the currently circulating omicron subvariants are resistant to this therapy. Please contact your primary care physician if you have any questions.
Markdown	[Skip to main content](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#main-content) Explore links (header) Explore UCLA Health - [UCLA Health Home](https://www.uclahealth.org/) - [About Us](https://www.uclahealth.org/discover/about) - [Cancer Center](https://www.uclahealth.org/cancer) - [Hospitals & Clinics](https://www.uclahealth.org/locations) - [School of Medicine](https://medschool.ucla.edu/) - [Academic Departments](https://www.uclahealth.org/departments) - [News & Insights](https://www.uclahealth.org/news) - [Community & Equity](https://www.uclahealth.org/community-equity) [Refer a Patient](https://www.uclahealth.org/discover/healthcare-professionals) Universal links (header) [myUCLAhealth](https://www.uclahealth.org/myuclahealth/nojs "myUCLAhealth Login.") [Contact Us](https://www.uclahealth.org/contact-us) Translate - [English](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [العربية](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [中文](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [Italiano](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [日本語](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [한국어](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [فارسی](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [Русский](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [Español](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [Tiếng Việt](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) Translate - [English](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [العربية](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [中文](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [Italiano](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [日本語](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [한국어](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [فارسی](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [Русский](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [Español](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) - [Tiếng Việt](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments#nolink) [![UCLA Health](https://www.uclahealth.org/themes/custom/uclahealth/dist/images/ucla-health-logo.svg)](https://www.uclahealth.org/) Primary navigation [Find Care](https://www.uclahealth.org/find-care/appointments) \> - [Find a Doctor](https://www.uclahealth.org/providers) - [Find a Location](https://www.uclahealth.org/locations) - [Virtual Care](https://www.uclahealth.org/find-care/appointments/virtual-care) - [Make an Appointment](https://www.uclahealth.org/find-care/appointments) - [Second Opinion Consults](https://www.uclahealth.org/find-care/appointments/second-opinion-consults) - [Medical Services](https://www.uclahealth.org/medical-services) - [Cancer Medical Services](https://www.uclahealth.org/cancer/cancer-services) - [Clinical Trials](https://www.uclahealth.org/clinical-trials) - [Wellness & Routine Care](https://www.uclahealth.org/patient-resources/support-information/patient-education/annual-health-wellness-screenings) [Patient Resources](https://www.uclahealth.org/patient-resources) \> - [Prepare for Your Visit](https://www.uclahealth.org/patient-resources/prepare-your-visit) - [Billing & Insurance](https://www.uclahealth.org/patient-resources/billing-insurance) - [Support & Information](https://www.uclahealth.org/patient-resources/support-information) - [Patient Portal (myUCLAhealth) & Medical Records](https://www.uclahealth.org/patient-resources/medical-records) - [Help Paying Your Bill](https://www.uclahealth.org/patient-resources/billing-insurance/financial-assistance-program/hospital-services-help-paying-your-bill) - [International Services](https://www.uclahealth.org/international-services) - [Patient Scam Alert](https://www.uclahealth.org/patient-resources/patient-scam-alert) [Locations](https://www.uclahealth.org/locations/search) \> - [Immediate Care](https://www.uclahealth.org/locations/immediate-care) - [Primary Care](https://www.uclahealth.org/locations/search?s=&f%5B0%5D=type%3A741) - [Pediatric Care](https://www.uclahealth.org/locations/search?s=&f%5B0%5D=type%3A781) - [Cancer Care](https://www.uclahealth.org/cancer/locations) - [Surgical Centers](https://www.uclahealth.org/locations/search?s=&f%5B0%5D=type%3A761 "See a list of outpatient surgical centers at UCLA Health") - [Imaging/Radiology](https://www.uclahealth.org/locations/search?s=&f%5B0%5D=type%3A786) - [Hospitals](https://www.uclahealth.org/locations/search?f%5B0%5D=type%3A751) - [All Locations](https://www.uclahealth.org/locations) [Discover](https://www.uclahealth.org/discover/about) \> - [About UCLA Health](https://www.uclahealth.org/discover/about) - [News & Insights](https://www.uclahealth.org/news) - [Patient Stories](https://www.uclahealth.org/news/search?f%5B0%5D=type%3A80636) - [Events Calendar](https://www.uclahealth.org/events) - [Donate to UCLA Health](https://www.uclahealth.org/giving) - [Work at UCLA Health](https://www.uclahealth.org/human-resources) - [For Health Care Professionals](https://www.uclahealth.org/discover/healthcare-professionals) - [Connect with UCLA Health](https://www.uclahealth.org/discover-ucla-health/connect) [Find a Doctor](https://www.uclahealth.org/providers) Primary navigation (mobile) [Find a Doctor](https://www.uclahealth.org/providers) [Find Care](https://www.uclahealth.org/find-care/appointments) - [Find a Doctor](https://www.uclahealth.org/providers) - [Find a Location](https://www.uclahealth.org/locations) - [Virtual Care](https://www.uclahealth.org/find-care/appointments/virtual-care) - [Make an Appointment](https://www.uclahealth.org/find-care/appointments) - [Second Opinion Consults](https://www.uclahealth.org/find-care/appointments/second-opinion-consults) - [Medical Services](https://www.uclahealth.org/medical-services) - [Cancer Medical Services](https://www.uclahealth.org/cancer/cancer-services) - [Clinical Trials](https://www.uclahealth.org/clinical-trials) - [Wellness & Routine Care](https://www.uclahealth.org/patient-resources/support-information/patient-education/annual-health-wellness-screenings) [Patient Resources](https://www.uclahealth.org/patient-resources) - [Prepare for Your Visit](https://www.uclahealth.org/patient-resources/prepare-your-visit) - [Billing & Insurance](https://www.uclahealth.org/patient-resources/billing-insurance) - [Support & Information](https://www.uclahealth.org/patient-resources/support-information) - [Patient Portal (myUCLAhealth) & Medical Records](https://www.uclahealth.org/patient-resources/medical-records) - [Help Paying Your Bill](https://www.uclahealth.org/patient-resources/billing-insurance/financial-assistance-program/hospital-services-help-paying-your-bill) - [International Services](https://www.uclahealth.org/international-services) - [Patient Scam Alert](https://www.uclahealth.org/patient-resources/patient-scam-alert) [Locations](https://www.uclahealth.org/locations/search) - [Immediate Care](https://www.uclahealth.org/locations/immediate-care) - [Primary Care](https://www.uclahealth.org/locations/search?s=&f%5B0%5D=type%3A741) - [Pediatric Care](https://www.uclahealth.org/locations/search?s=&f%5B0%5D=type%3A781) - [Cancer Care](https://www.uclahealth.org/cancer/locations) - [Surgical Centers](https://www.uclahealth.org/locations/search?s=&f%5B0%5D=type%3A761 "See a list of outpatient surgical centers at UCLA Health") - [Imaging/Radiology](https://www.uclahealth.org/locations/search?s=&f%5B0%5D=type%3A786) - [Hospitals](https://www.uclahealth.org/locations/search?f%5B0%5D=type%3A751) - [All Locations](https://www.uclahealth.org/locations) [Discover](https://www.uclahealth.org/discover/about) - [About UCLA Health](https://www.uclahealth.org/discover/about) - [News & Insights](https://www.uclahealth.org/news) - [Patient Stories](https://www.uclahealth.org/news/search?f%5B0%5D=type%3A80636) - [Events Calendar](https://www.uclahealth.org/events) - [Donate to UCLA Health](https://www.uclahealth.org/giving) - [Work at UCLA Health](https://www.uclahealth.org/human-resources) - [For Health Care Professionals](https://www.uclahealth.org/discover/healthcare-professionals) - [Connect with UCLA Health](https://www.uclahealth.org/discover-ucla-health/connect) Explore links (mobile) Explore UCLA Health - [UCLA Health Home](https://www.uclahealth.org/) - [About Us](https://www.uclahealth.org/discover/about) - [Cancer Center](https://www.uclahealth.org/cancer) - [Hospitals & Clinics](https://www.uclahealth.org/locations) - [School of Medicine](https://medschool.ucla.edu/) - [Academic Departments](https://www.uclahealth.org/departments) - [News & Insights](https://www.uclahealth.org/news) - [Community & Equity](https://www.uclahealth.org/community-equity) [Refer a Patient](https://www.uclahealth.org/discover/healthcare-professionals) Universal links (mobile) [myUCLAhealth](https://www.uclahealth.org/myuclahealth/nojs "myUCLAhealth Login.") [Contact Us](https://www.uclahealth.org/contact-us) Breadcrumb 1. [Home](https://www.uclahealth.org/) # COVID-19 Outpatient Treatments ## Sub-navigation ## [COVID-19 Info](https://www.uclahealth.org/treatment-options/coronavirus) - [Vaccine Info Hub](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-vaccine-info-hub) - [COVID-19 Positive](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-positive) - [COVID-19 Outpatient Treatments](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments) - [FAQ](https://www.uclahealth.org/treatment-options/covid-19-info/faq) - [Symptoms](https://www.uclahealth.org/treatment-options/covid-19-info/faq/symptoms) - [Testing](https://www.uclahealth.org/treatment-options/covid-19-info/faq/testing) - [COVID-19 Positive](https://www.uclahealth.org/treatment-options/covid-19-info/faq/covid-19-positive) - [Treatment](https://www.uclahealth.org/treatment-options/covid-19-info/faq/treatment) - [Vaccine](https://www.uclahealth.org/treatment-options/covid-19-info/faq/vaccine) - [Immunity](https://www.uclahealth.org/treatment-options/covid-19-info/faq/immunity) - [Appointments & Visitor Guidelines](https://www.uclahealth.org/treatment-options/covid-19-info/faq/appointments-visitor-guidelines) - [Pregnancy & COVID-19](https://www.uclahealth.org/treatment-options/covid-19-info/faq/pregnancy-covid-19) - [Addressing Concerns](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-vaccine-addressing-concerns) [COVID-19 Info](https://www.uclahealth.org/treatment-options/coronavirus) - [Vaccine Info Hub](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-vaccine-info-hub) - [COVID-19 Positive](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-positive) - [COVID-19 Outpatient Treatments](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-outpatient-treatments) - [FAQ](https://www.uclahealth.org/treatment-options/covid-19-info/faq) - [Symptoms](https://www.uclahealth.org/treatment-options/covid-19-info/faq/symptoms) - [Testing](https://www.uclahealth.org/treatment-options/covid-19-info/faq/testing) - [COVID-19 Positive](https://www.uclahealth.org/treatment-options/covid-19-info/faq/covid-19-positive) - [Treatment](https://www.uclahealth.org/treatment-options/covid-19-info/faq/treatment) - [Vaccine](https://www.uclahealth.org/treatment-options/covid-19-info/faq/vaccine) - [Immunity](https://www.uclahealth.org/treatment-options/covid-19-info/faq/immunity) - [Appointments & Visitor Guidelines](https://www.uclahealth.org/treatment-options/covid-19-info/faq/appointments-visitor-guidelines) - [Pregnancy & COVID-19](https://www.uclahealth.org/treatment-options/covid-19-info/faq/pregnancy-covid-19) - [Addressing Concerns](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-vaccine-addressing-concerns) ## Coronavirus Outpatient Treatments There are several therapies meant to prevent COVID-19 patients with high-risk medical conditions from becoming hospitalized, as follows: Paxlovid: Paxlovid is a FDA-approved oral treatment for mild-to-moderate COVID-19. Patients with COVID-19 who have had symptoms for 5 days or fewer and are at high-risk for disease progression should consider Paxlovid under a doctor's supervision. A close evaluation of drug interactions should be reviewed prior to taking Paxlovid. Remdesivir: If we cannot offer Paxlovid due to potential drug interactions, a process is in place to offer high-risk patients who meet the below criteria a three-day course of remdesivir via IV through our outpatient treatment program. Three days of IV remdesivir has been shown to reduce the risk of hospitalization by 87% and is similar in efficacy to Paxlovid. While Paxlovid is easier to administer, [the National Institutes of Health (NIH) lists three days of remdesivir as an option Link is external, Link opens in new window](https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/) for patients at risk of COVID-19 disease progression. Monoclonal antibody therapies: As of Nov. 21, 2022, UCLA Health no longer uses bebtelovimab to treat COVID-19, as the currently circulating strains of the omicron variant are resistant to this monoclonal antibody therapy. Molnupiravir: High-risk patients with COVID-19 who are ineligible for Paxlovid and don't meet the high-risk criteria for remdesivir may be given an anti-viral pill called molnupiravir (Lagevrio) to prevent hospitalization. Watch video: outpatient COVID-19 therapies Cost information for COVID outpatient treatments: COVID-19 medications are currently being provided to patients at no cost[. While we are billing insurers for the administration of remdesivir, there should be no cost share for patients.]() Want more information? Please reach out to your primary care physician if you have questions about outpatient COVID-19 therapies. Please see the [COVID-19 vaccine info hub](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-vaccine-info-hub) for information about the available vaccines. ### High-risk criteria for remdesivir: Patients with the following high-risk conditions who are otherwise ineligible for Paxlovid due to drug interactions or a creatine clearance of \<30 may be eligible to receive remdesivir through our outpatient treatment program. - Patients who are within one year of receiving B-cell depleting therapies (e.g., rituximab, ocrelizumab, ofatumumab, alemtuzumab) - Patients receiving Bruton tyrosine kinase inhibitors (e.g. ibrutinib, acalabrutinib, zanubrutinib) - Chimeric antigen receptor T cell recipients (CAR-T) - Post-hematopoietic cell transplant recipients who have chronic graft versus host disease or who are taking immunosuppressive medications for another indication - Patients with hematologic malignancies who are on active chemotherapy - Any solid organ transplant recipient - Patients with severe combined immunodeficiencies - Patients with untreated HIV who have a CD4 T lymphocyte cell count \<200 cells/mm3 - Patients in active cancer treatment for non-hematologic malignancies (e.g. myelosuppressive chemotherapy) - Post-hematopoietic cell transplant recipients who received treatment within two years without GVHD / not taking immunosuppressive medications for another indication - Patients actively being treated with high-dose corticosteroids of more than 20 mg daily for at least two weeks, or actively taking other drugs (within one month) that may suppress their immune response - Patients with pulmonary arterial hypertension on phosphodiesterase inhibitors and on chronic oxygen - Patients who are unvaccinated who have traditional high-risk co-morbid conditions such as obesity or heart, kidney or lung disease ### Monoclonal antibody therapy for pre-exposure prophylaxis As of Nov. 21, 2022, UCLA Health will no longer accept new referrals for AstraZeneca's Evusheld (tixagevimab/cilgavimab), the FDA authorized monoclonal antibody for pre-exposure prevention of COVID-19, as the currently circulating omicron subvariants are resistant to this therapy. Please contact your primary care physician if you have any questions. [![UCLA Health](https://www.uclahealth.org/themes/custom/uclahealth/dist/images/ucla-health-logo-footer.svg)](https://www.uclahealth.org/) - ### CONNECT WITH US - [Contact Us](https://www.uclahealth.org/contact-us) - [Share Your Feedback](https://connect.uclahealth.org/send-a-care-compliment/) - [International Services](https://www.uclahealth.org/international-services) - [中文](https://cn.uclahealth.org/) - [العربية](https://mena.uclahealth.org/) - [myUCLAhealth](https://www.uclahealth.org/myuclahealth/nojs) - [Get the UCLA Health Apps](https://www.uclahealth.org/patient-resources/support-information/apps) - ### FIND CARE - [Find a Doctor](https://www.uclahealth.org/providers) - [Find a Location](https://www.uclahealth.org/locations "/patients-families/find-a-location") - [Immediate Care](https://www.uclahealth.org/locations/immediate-care) - [Emergency Care](https://www.uclahealth.org/emergency) - [Make an Appointment](https://www.uclahealth.org/find-care/appointments) - [Medical Services](https://www.uclahealth.org/medical-services) - [Clinical Trials](https://www.uclahealth.org/clinical-trials) - ### PATIENT RESOURCES - [Prepare for Your Visit](https://www.uclahealth.org/patient-resources/prepare-your-visit) - [Visitor Guidelines](https://www.uclahealth.org/patient-resources/visitor-guidelines) - [Patient Education](https://www.uclahealth.org/patient-resources/support-information/patient-education) - [Billing & Insurance](https://www.uclahealth.org/patient-resources/billing-insurance) - [Help Paying Your Bill](https://www.uclahealth.org/patient-resources/billing-insurance/financial-assistance-program/hospital-services-help-paying-your-bill) - [Price Transparency](https://www.uclahealth.org/patient-resources/billing-insurance/price-transparency/machine-readable-files) - [Support & Information](https://www.uclahealth.org/patient-resources/support-information) - [COVID-19 Info](https://www.uclahealth.org/treatment-options/coronavirus) - [Wellness & Routine Care](https://www.uclahealth.org/patient-resources/support-information/patient-education/annual-health-wellness-screenings) - ### DISCOVER UCLA HEALTH - [About UCLA Health](https://www.uclahealth.org/discover/about) - [Departments](https://www.uclahealth.org/departments) - [News, Insights and Patient Stories](https://www.uclahealth.org/news) - [For Health Care Professionals](https://www.uclahealth.org/discover/healthcare-professionals) - [Community, Equity and Inclusive Excellence](https://www.uclahealth.org/discover/about/hedi) - [Contact Media Team](https://www.uclahealth.org/news/journalist-resources) - [Donate to UCLA Health](https://www.uclahealth.org/giving) - [Work at UCLA Health](https://www.uclahealthcareers.org/) - [Volunteer for UCLA Health](https://www.uclahealth.org/volunteer) - [Facebook](https://www.facebook.com/uclahealth) - [X-Twitter](https://x.com/uclahealth) - [Instagram](https://instagram.com/uclahealth) - [YouTube](https://youtube.com/ucla-health) - [LinkedIn](https://linkedin.com/company/ucla-health) - [Weibo](https://weibo.com/UCLAHealth) ## Policy links (footer) - [HIPAA Notice](https://www.uclahealth.org/privacy-practices) - [Privacy Notice](https://www.uclahealth.org/privacy-notice) - [Nondiscrimination](https://www.uclahealth.org/nondiscrimination) - [Report Misconduct](https://www.uclahealth.org/reporting-misconduct) - [We listen. We care.](https://www.uclahealth.org/patient-resources/support-information/patient-experience/we-listen-we-care) © 2026 UCLA Health
Readable Markdown	## Coronavirus Outpatient Treatments There are several therapies meant to prevent COVID-19 patients with high-risk medical conditions from becoming hospitalized, as follows: Paxlovid: Paxlovid is a FDA-approved oral treatment for mild-to-moderate COVID-19. Patients with COVID-19 who have had symptoms for 5 days or fewer and are at high-risk for disease progression should consider Paxlovid under a doctor's supervision. A close evaluation of drug interactions should be reviewed prior to taking Paxlovid. Remdesivir: If we cannot offer Paxlovid due to potential drug interactions, a process is in place to offer high-risk patients who meet the below criteria a three-day course of remdesivir via IV through our outpatient treatment program. Three days of IV remdesivir has been shown to reduce the risk of hospitalization by 87% and is similar in efficacy to Paxlovid. While Paxlovid is easier to administer, [the National Institutes of Health (NIH) lists three days of remdesivir as an option Link is external, Link opens in new window](https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/) for patients at risk of COVID-19 disease progression. Monoclonal antibody therapies: As of Nov. 21, 2022, UCLA Health no longer uses bebtelovimab to treat COVID-19, as the currently circulating strains of the omicron variant are resistant to this monoclonal antibody therapy. Molnupiravir: High-risk patients with COVID-19 who are ineligible for Paxlovid and don't meet the high-risk criteria for remdesivir may be given an anti-viral pill called molnupiravir (Lagevrio) to prevent hospitalization. Watch video: outpatient COVID-19 therapies Cost information for COVID outpatient treatments: COVID-19 medications are currently being provided to patients at no cost[. While we are billing insurers for the administration of remdesivir, there should be no cost share for patients.]() Want more information? Please reach out to your primary care physician if you have questions about outpatient COVID-19 therapies. Please see the [COVID-19 vaccine info hub](https://www.uclahealth.org/treatment-options/covid-19-info/covid-19-vaccine-info-hub) for information about the available vaccines. ### High-risk criteria for remdesivir: Patients with the following high-risk conditions who are otherwise ineligible for Paxlovid due to drug interactions or a creatine clearance of \<30 may be eligible to receive remdesivir through our outpatient treatment program. - Patients who are within one year of receiving B-cell depleting therapies (e.g., rituximab, ocrelizumab, ofatumumab, alemtuzumab) - Patients receiving Bruton tyrosine kinase inhibitors (e.g. ibrutinib, acalabrutinib, zanubrutinib) - Chimeric antigen receptor T cell recipients (CAR-T) - Post-hematopoietic cell transplant recipients who have chronic graft versus host disease or who are taking immunosuppressive medications for another indication - Patients with hematologic malignancies who are on active chemotherapy - Any solid organ transplant recipient - Patients with severe combined immunodeficiencies - Patients with untreated HIV who have a CD4 T lymphocyte cell count \<200 cells/mm3 - Patients in active cancer treatment for non-hematologic malignancies (e.g. myelosuppressive chemotherapy) - Post-hematopoietic cell transplant recipients who received treatment within two years without GVHD / not taking immunosuppressive medications for another indication - Patients actively being treated with high-dose corticosteroids of more than 20 mg daily for at least two weeks, or actively taking other drugs (within one month) that may suppress their immune response - Patients with pulmonary arterial hypertension on phosphodiesterase inhibitors and on chronic oxygen - Patients who are unvaccinated who have traditional high-risk co-morbid conditions such as obesity or heart, kidney or lung disease ### Monoclonal antibody therapy for pre-exposure prophylaxis As of Nov. 21, 2022, UCLA Health will no longer accept new referrals for AstraZeneca's Evusheld (tixagevimab/cilgavimab), the FDA authorized monoclonal antibody for pre-exposure prevention of COVID-19, as the currently circulating omicron subvariants are resistant to this therapy. Please contact your primary care physician if you have any questions.
Shard	170 (laksa)
Root Hash	15898094397791395770
Unparsed URL	org,uclahealth!www,/treatment-options/covid-19-info/covid-19-outpatient-treatments s443